Kedokteran & Kesehatan editorial
Open AccessOA2022
Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial
In the COSMOS trial of 21,442 older adults, cocoa extract supplementation (500 mg flavanols/day) did not significantly reduce total cardiovascular events (HR 0.90; 95% CI 0.78โ1.02) over a median 3.6 years, but was associated with a 27% lower risk of cardiovascular death (HR 0.73; 95% CI 0.54โ0.98).
H. Sesso; J. Manson; A. Aragaki; Pamela M. Rist; Lisa G. Johnson; G. Friedenberg; Trisha Copeland; Allison Clar; Samia Mora; M. V. Moorthy; A. Sarkissian; William R. Carrick; Garnet L. Andersonยท American Journal of Clinical Nutritionยท 2022ยท DOI 10.1093/ajcn/nqac055
The core problem
Cocoa extract is a rich source of flavanols, plant compounds that have been shown in small, short-term trials to favorably influence vascular risk factors such as blood pressure and endothelial function. However, whether long-term cocoa flavanol supplementation can reduce clinical cardiovascular disease (CVD) events remained untested. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS) was designed to address this gap by evaluating the effects of cocoa extract supplementation on total CVD and cancer in a large population of older adults. This digest reports on the cocoa extract intervention arm of the trial.
Innovation
COSMOS was a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of cocoa extract supplementation and multivitamins for the prevention of CVD and cancer. The trial enrolled 21,442 US adults (12,666 women aged โฅ65 years and 8,776 men aged โฅ60 years) who were free of major CVD and recently diagnosed cancer. The intervention phase ran from June 2015 through December 2020. Participants were randomly assigned to receive either a cocoa extract supplement providing 500 mg flavanols per day (including 80 mg (โ)-epicatechin) or a placebo. The primary outcome was a composite of confirmed incident total cardiovascular events, including myocardial infarction (MI), stroke, coronary revascularization, cardiovascular death, carotid artery disease, peripheral artery surgery, and unstable angina. Secondary endpoints included individual cardiovascular events and all-cause mortality. The trial is registered at ClinicalTrials.gov as NCT02422745.
Introduction
Cocoa extract is a rich source of flavanols, plant compounds that have been shown in small, short-term trials to favorably influence vascular risk factors such as blood pressure and endothelial function. However, whether long-term cocoa flavanol supplementation can reduce clinical cardiovascular disease (CVD) events remained untested. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS) was designed to address this gap by evaluating the effects of cocoa extract supplementation on total CVD and cancer in a large population of older adults. This digest reports on the cocoa extract intervention arm of the trial.
Why it matters
The COSMOS trial found that cocoa extract supplementation did not significantly reduce total cardiovascular events among older adults, although the point estimate suggested a 10% reduction that was not statistically significant. Notably, there was a statistically significant 27% reduction in cardiovascular death, a secondary endpoint. The per-protocol analysis, which accounts for nonadherence, also supported a potential reduction in total cardiovascular events. These findings are consistent with the favorable effects of cocoa flavanols on vascular risk factors observed in shorter trials, but the modest and non-significant primary result warrants caution. The authors conclude that additional research is needed to clarify whether cocoa extract may reduce clinical cardiovascular events. The trial's large sample size, long duration, and rigorous design are strengths, but the median follow-up of 3.6 years may have been insufficient to detect small effects on total CVD events. Furthermore, the study population was generally healthy at baseline, which may limit generalizability to higher-risk groups.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ